How has been the historical performance of the Beryl Drugs?

Answer:The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years. Breakdown: Beryl Drugs' net sales have seen a decline from Rs 26.89 crore in Mar'23 to Rs 21.15 crore in Mar'25, following a peak of Rs 26.73 crore in Mar'24. Other operating income has increased from Rs 0.27 crore in Mar'23 to Rs 1.41 crore in Mar'25, contributing to a total operating income of Rs 22.56 crore in Mar'25, down from Rs 27.16 crore in Mar'23. The total expenditure, excluding depreciation, also decreased to Rs 19.91 crore in Mar'25 from Rs 24.95 crore in Mar'23. Operating profit (PBDIT) remained relatively stable at Rs 2.65 crore in Mar'25 compared to Rs 2.21 crore in Mar'23. Profit before tax showed a slight decrease from Rs 0.98 crore in Mar'23 to Rs 0.87 crore in Mar'25, while profit after tax also fell from Rs 0.77 crore in Mar'23 to Rs 0.58 crore in Mar'25. The earnings per share (EPS) decreased to Rs 1.14 in Mar'25 from Rs 1.52 in Mar'24, reflecting the overall decline in profitability. On the balance sheet, total liabilities remained stable at Rs 17.38 crore in Mar'24, while total assets slightly decreased to Rs 17.38 crore from Rs 17.39 crore in Mar'23. The book value per share increased to Rs 17.52 in Mar'24 from Rs 15.84 in Mar'23, indicating a strengthening of shareholder equity despite the operational challenges.